Jubilant Life hits record high

By Research Desk
about 8 years ago

Jubilant Life Sciences has been scaling new highs since 18th of August and today too it hit a record high at Rs.546.70. It continues to remain around the Rs,540 levels, up almost 7%.

Today morning, before the opening bell, the company announced that it has received Abbreviated New Drug Application (ANDA) final approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil Tablets of AstraZeneca, which is used for the treatment of hypertension.

As on June 30, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally. This includes 70 ANDAs filed in the US, of which 44 have been approved and 104 filings in Europe.